Langenfeld, Germany – ARTES Biotechnology, the German-based biopharmaceutical CDMO for microbial cell lines and process development, will exhibit at the world’s premier biotechnology event, the BIO International Convention, this time in June in Boston, USA.
ARTES will be part of the German Pavilion at Location #3065 at the Boston Convention & Exhibition Center.
At BIO, ARTES will present its strengths in CDMO services. Of particular note are the various technology platforms for the development of microbial recombinant cell line and the process development for the production of various target products, including vaccines, biopharmaceuticals, biosimilars, and/or enzymes.
Another focus will be on the broad portfolio of pre-developed and therefore immediately transferable processes for enzymes, vaccines, and biosimilars.
Reliable and affordable services
The delegates from ARTES, Managing Director Dr. Michael Piontek and Business Development Director Dr. Melanie Piontek, will use the networking events at BIO to find new partnerships and applications for ARTES’ advanced capabilities.
ARTES´ team of expert scientists, engineers and technicians works in a lean, cost-effective structure. High quality standards deliver development reports and documentation as basis for our clients´ product registration with the relevant authorities.
Successful vaccine platforms
This is shown in a most recent project with Serum Institute of India. The R21/Matrix-M™ malaria vaccine launched in 2024 is the latest success story of ARTES vaccine technology and CDMO work. The vaccine platform enables efficient expression, folding and presentation of target antigens on the surface of chimeric VLPs. This improves recognition and uptake by antigen-presenting cells, leading to a strong immune response against the respective target antigen in the target organism.
At BIO International visitors are invited to get a closer look into the ARTES service portfolio.
